Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism-a randomized comparative study

Contraception

Volumn 79, Issue 1, 2009, Pages 24-28

  Ng, Ying Woo ^a   Liang, Shen ^b   Singh, Kuldip ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Lipid metabolism; LNG IUS; Progestins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; NORMAL HUMAN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; LIPID METABOLISM; LIPIDS; TRIGLYCERIDES; YOUNG ADULT;

EID: 56549108928     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.07.012     Document Type: Article

References (20)

1. Andersson J.K., and Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 97 (1990) 690-694
2. Raudaskoskia T., Tapanainena T., Tomás E., et al. Intrauterine 10 mg and 20 mg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 109 (2002) 136-144
3. Spinnato J.A. Mechanism of action of intrauterine contraceptive device and its relation to informed consent. Am J Obstet Gynecol 176 (1997) 503-506
4. Kuller L.H., Meilahn E., Bunker C., Yong L.C., Sutton-Tyrrell K., and Matthews K. Development of risk factors for cardiovascular disease among women from adolescence to older ages. Am J Med Sci 310 Suppl 1 (1995) S91-S100
5. Nilsson C.G., Kostiainen E., and Ehnholm C. Serum lipids and high density lipoprotein cholesterol in women on long-term sustained low-dose IUD treatment with levonorgestrel. Int J Fertil 26 (1981) 135-137
6. Kayikcioglu F., Gunes M., Ozdegirmenci O., and Haberal A. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception 73 (2006) 528-531
7. Rogovskaya S., Rivera R., Grimes D.A., et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 105 (2005) 811-815
8. Michal F, editor. Safety requirements for contraceptive steroids. New York: Cambridge University Press; 1989. p. xv, 467.
9. Friedewald W.I., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18 (1982) 499-502
10. Wynn V., and Niththyananthan R. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high density lipoproteins. Am J Obstet Gynecol 142 6 Pt 2 (1982) 766-771
11. Slone D., Shapiro S., Kaufman D.W., Rosenberg L., Miettinen O.S., and Stolley P.D. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 305 (1981) 402-404
12. Wahl P., Walden C., Knopp R., et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 308 (1983) 862-867
13. Biswas A., Viegas O.A.C., and Roy A.C. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids - a randomized comparative study. Contraception 68 (2003) 189-193
14. Singh K., and Ratnam S.S. A comparison of the clinical performance, contraceptive efficacy, reversibility and acceptability of Norplant implants and Ortho Gynae T380 intrauterine copper contraceptive device. Adv Contracep 13 (1997) 385-393
15. Singh K., and Ratnam S.S. A study on the effects of Norplant implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women. Contraception 56 (1997) 77-83
16. Graff-Iversen S., and Tonstad S. Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey. Contraception 66 (2002) 7-13
17. Rabe T., Thuro H.C., Goebel K., Borchardt C., Grunwald K., and Runnebaum B. Lipid metabolism in Norplant-2 users - a two-year follow-up study. Total cholesterol, triglycerides, lipoproteins and apolipoproteins. Contraception 45 (1992) 21-37
18. Ingelsson E., Schaefer E.J., Contios J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007) 776-785
19. Mascarenhas L., van Beek A., Bennink H.C., and Newton J. Twenty-four months comparison of apolipoproteins A-I, A-II and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. Contraception 58 (1998) 215-219
20. Suherman S.K., Affandi B., and Korver T. The effect of implanon on lipid metabolism in comparison with Norplant. Contraception 60 (1999) 281-287